|
| Vaccine brand | Platform | Efficacy | Safety | Impact on transmissibility | Effectiveness against variants | References |
|
Pfizer–BioNTech
(mRNA-1273) | mRNA vaccines | High against severe infection, moderate against symptomatic disease | All individuals aged 6 months and above. Rare serious adverse event of mild myocarditis in young males aged 18–35 after the second dose | Modest | Low against for omicron variant | [63, 90, 91], |
| Moderna vaccines (BNT162b2) | High against severe infection, Moderate against symptomatic disease | Vaccine for emergency use.
Rare mild myocarditis in young males aged 18–35 after the second dose | Modest | Low for the omicron variant | [63, 5] |
|
Novavax
(NVX-CoV2373) | Subunit vaccine | High against severe infection | All individuals aged 12 and above. Infrequent adverse severe events of anaphylaxis, paresthesia, hypesthesia, myocarditis, and pericarditis were reported | No substantive data are available | High against alpha, beta, and delta variants. No data are available for the omicron variant | [92, 93] |
|
| Soberana plus vaccine (Soberana 02 vaccine) | Conjugate vaccine (recombinant RBD conjugated to tetanus toxoid) | High against severe infection, moderate against symptomatic disease | All individuals aged 19–80 years, for emergency use only, transient or mild discomfort | Modest | Effective against delta variant. Data are not available for other variants | [63, 94], |
|
Sinopharm
Beijing Bio-Institute of Biological Products
(BBIBP-CorV) | Whole inactivated virus | Efficacy trials are underway, but data are not available yet | All individuals aged 18 and above. Not suitable for an individual with a history of anaphylaxis | No substantive data are available | No substantive data are available | [95, 96] |
|
Oxford/AstraZeneca ChAdOx1-S
(ChAdOx1 nCoV-19/ Covishield) | Recombinant vaccine | High against severe infection and symptomatic infection | All individuals aged 18 and above. Not suitable for an individual with a history of severe allergic reactions.
Rare cases of Guillain–Barré syndrome (GBS), thrombosis with thrombocytopenia syndrome (TTS) were reported | No substantive data are available | Effective against alpha variant No substantive data available for other variants | [97] |
|
| Sinovac-CoronaVac (CoronaVac) | Whole inactivated virus | High against severe infection | All individuals aged three and above. Mild and local side effects. It is recommended for emergency use only | No substantive data are available | No substantive data are available | [98, 99] |
|
| Janssen Ad26.COV2.S | Nonreplicating adenovirus vector | High against severe infection | All individuals aged 18 and above. Not suitable for an individual with a history of severe allergic reactions. Rare cases of Guillain–Barré syndrome (GBS), thrombosis with thrombocytopenia syndrome (TTS) were reported | No substantive data are available | High against B1.351 and P.2. No data available for the omicron variant | [63, 100] |
|
| Bharat Biotech BBV152 COVAXIN | Whole inactivated virus | High against severe infection, moderate against symptomatic disease | All individuals aged 18 and above. Not suitable for an individual with a history of anaphylaxis | No substantive data are available | High against all variant-related COVID-19 diseases. No data yet for omicron | [96, 101], |
|
| Sputnik V or Gam-COVID-Vac | Nonreplicating adenovirus vector
(first registered combination vector vaccine) | High against severe infection, not reported against symptomatic disease | All individuals aged 18 and above | No substantive data are available | No substantive data are available | [96, 102], |
|
